Who is eligible for clinical trial NCT06958211?

Participants must meet the protocol's inclusion criteria for Hidradenitis Suppurativa. The stated age range is 12 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06958211 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-07

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (NCT06958211)

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Incyte Corporation

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).

Location: Investigative Site US257 — Birmingham, Alabama

Age range: 12 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Diagnosis of HS for at least 6 months prior to screening visit.
Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:
A total AN count of at least 4, with no draining tunnels AND
Affecting at least 2 distinct anatomical areas
Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.
Further inclusion criteria apply.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Body surface areas to be treated exceed 20% BSA at screening or baseline
Presence of draining tunnels at screening or baseline.
Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
Laboratory values outside of the protocol-defined criteria.
Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
Further exclusion criteria apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (107 Sites)

Showing the first 25 of 107 sites.

Investigative Site US257 — Birmingham, Alabama
Investigative Site US218 — Birmingham, Alabama
Investigative Site US239 — Montgomery, Alabama
Investigative Site US215 — Phoenix, Arizona
Investigative Site US261 — Phoenix, Arizona
Investigative Site US240 — Tucson, Arizona
Investigative Site US262 — Encino, California
Investigative Site US222 — Fountain Valley, California
Investigative Site US211 — Los Angeles, California
Investigative Site US237 — Los Angeles, California
Investigative Site US234 — Northridge, California
Investigative Site US250 — Santa Ana, California
Investigative Site US244 — Castle Rock, Colorado
Investigative Site US252 — Cromwell, Connecticut
Investigative Site US208 — Boca Raton, Florida
Investigative Site US203 — Hialeah, Florida
Investigative Site US258 — Jacksonville, Florida
Investigative Site US206 — Maitland, Florida
Investigative Site US223 — Miami, Florida
Investigative Site US241 — Miami, Florida
Investigative Site US202 — Miami, Florida
Investigative Site US214 — Tampa, Florida
Investigative Site US247 — Tampa, Florida
Investigative Site US231 — Columbus, Georgia
Investigative Site US225 — Sandy Springs, Georgia

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

Real-world Secukinumab Outcomes in Canadian HS Patients — Calgary, Alberta
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — Phoenix, Arizona
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa — Phoenix, Arizona
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. — Birmingham, Alabama
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository — San Francisco, California

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗